Stef van Grieken, Co-founder and CEO of Cradle, spearheads AI innovations in protein engineering for drug development. They delve into the rapid growth of Cradle, fueled by a $100M funding round, and discuss the complexities of AI's integration into drug discovery. Stef highlights the challenges of selling SaaS to pharma and the critical need for effective lab automation. With insights into future trends, he explores what the next 25 years hold for biotechnology and the evolving landscape of AI-driven drug development.